Saturday 17 October 2026
Export SLXN’s income statement to Excel — free account
Silexion Therapeutics Corp
SLXN Healthcare Biotechnology
In the quarter to June 2026, EPS grew 88.0%, free cash flow fell 16.6% and total debt fell 47.0%, each against the same quarter a year earlier.
0.15
0.04
−21.05%
Follow SLXN
| Dec '17 | Nov '20 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|
Current Ratio |
— | 0.29 | 0.43 | 1.17 | 0.08 | 2.27 | 0.64 | 2.41 |
Net Debt/EBITDA |
— | 0.00 | 0.26 | 0.04 | 0.05 | 1.00 | (0.14) | 0.38 |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 103.42% | 21.73% |
Debt/Equity |
— | — | 0.00 | 0.00 | 0.00 | 0.00 | (0.74) | 0.60 |
Asset Turnover |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF/Net income |
— | (0.62) | 0.38 | 1.86 | 1.40 | 0.92 | 0.51 | 0.91 |
Capex/Depreciation |
— | 0.00 | — | — | — | 1.47 | (0.88) | (0.64) |
Interest Coverage |
— | — | — | (147.48) | (0.73) | (11.85) | (3.19) | (41.99) |
| — | 0.00% | (0.34%) | 570.61% | (90.02%) | 74.55% | 204.96% | 1,718.90% | |
| — | (504.25%) | (189.18%) | (1.31%) | 0.50% | (8.10%) | (405.05%) | (236.40%) | |
ROIC |
— | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
— | 101.87% | 115.24% | (1,275.68%) | (49.78%) | (174.51%) | 1,322.85% | (305.12%) |
Research and Development Expense of Revenue |
— | 0.00% | — | — | — | 0.00% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
— | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
— | — | — | — | — | 0.00% | 0.00% | 0.00% |
Free Cash Flow per Share |
— | 0.00 | (83.33) | (586.33) | 326.56 | (6,375.71) | (2,004.29) | (81.41) |
Cash per Share |
— | — | 57.44 | 16.21 | 23.88 | 6,600.00 | 290.95 | 45.25 |
Shareholders Equity per Share |
— | — | (188.89) | (39.46) | (481.12) | 4,287.14 | (949.76) | 19.57 |
Interest Debt per Share |
— | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
— | — | (188.89) | (39.46) | (481.12) | 4,287.14 | (949.76) | 19.57 |
Free Cash Flow |
— | 0.12 | (0.07) | (1.41) | 0.82 | (4.46) | (8.42) | (10.83) |
Working Capital |
— | (0.19) | (0.17) | 0.06 | (1.17) | 2.78 | (1.27) | 3.88 |
Capital Expenditures |
— | 0.00 | — | — | — | 0.07 | (0.02) | (0.01) |
Net Current Asset Value |
— | (0.19) | (0.17) | (115.10) | (117.89) | 2.72 | (4.60) | 2.03 |
| Other line items | ||||||||
Quick Ratio |
— | 0.00 | 0.17 | 0.11 | 0.05 | 2.10 | 0.35 | 2.18 |
Depreciation/Fixed assets |
— | 0.00 | — | — | — | 0.92 | 0.83 | 0.56 |
Cash ROIC |
— | 0.00% | 63.40% | 2,521.86% | (71.42%) | (58.56%) | (4,339.18%) | (106.27%) |
Accounts Payable Turnover |
— | — | — | — | — | — | 0.00 | 0.00 |
Average Days of Payables |
— | — | — | — | — | 0.00 | 0.00 | 0.00 |
Revenue per Share |
— | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF per Share |
— | 0.00 | (83.33) | (586.33) | 326.56 | (6,470.00) | (1,999.05) | (81.35) |
Capex per Share |
— | 0.00 | 0.00 | 0.00 | 0.00 | 94.29 | (5.24) | (0.07) |
Average Payables |
— | — | — | — | — | — | 0.62 | 0.86 |
Average Assets |
— | 0.04 | 0.10 | 57.77 | 116.10 | 61.03 | 4.06 | 5.04 |
Average Common Equity |
— | — | 57.37 | (0.13) | (0.65) | (6.63) | (8.02) | (0.69) |
Capex to Sales |
— | 0.00 | — | — | — | 0.00 | 0.00 | 0.00 |
Columns are period end dates